Dipti Thakkar

700 citations

21 papers · 328 indexed · h-index 9

Co-authors: Andrew Carr Osnat Hakimi Piers J. Ingram Jerome D. Boyd‐Kirkup Amal Shervington Rahima Patel Tyler M. Grant Salma Chaudhury
Topics: Monoclonal and Polyclonal Antibodies Research (9 papers)Cancer Immunotherapy and Biomarkers (8 papers)Immune cells in cancer (4 papers)
Cited by: Orthopedics and Sports Medicine Developmental Biology Immunology
Journals: Journal of Clinical Oncology Blood The Journal of Immunology
Partner nations: United Kingdom United States Singapore

In The Last Decade

Dipti Thakkar

21 papers receiving 323 citations

Peers

Countries citing papers authored by Dipti Thakkar

Since Specialization

Citations

This map shows the geographic impact of Dipti Thakkar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dipti Thakkar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dipti Thakkar more than expected).

Fields of papers citing papers by Dipti Thakkar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dipti Thakkar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dipti Thakkar. The network helps show where Dipti Thakkar may publish in the future.

Co-authorship network of co-authors of Dipti Thakkar

This figure shows the co-authorship network connecting the top 25 collaborators of Dipti Thakkar. A scholar is included among the top collaborators of Dipti Thakkar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dipti Thakkar. Dipti Thakkar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Abstract 2660: HMBD-501 - a novel Fc engineered, exatecan-based next generation HER3 targeting antibody drug conjugate shows robust efficacy and tolerability in pre-clinical solid tumor models 2023 ·Cancer Research ·Suhail Ahmed Kabeer Rasheed,Dipti Thakkar,(unknown),(unknown),Akshaya Bansal,(unknown),(unknown),Brendon J. Hanson,Piers J. Ingram,Jerome D. Boyd‐Kirkup	2
2	Selective targeting of pathogenic auto-reactive VH4–34 B cells with a rationally developed anti-VH4–34 antibody offers a new therapeutic approach for autoimmune disorders 2023 ·The Journal of Immunology ·(unknown),Dipti Thakkar,(unknown),Warren Lee,(unknown),(unknown),Brendon J. Hanson,Konrad Paszkiewicz,Piers J. Ingram,Jerome D. Boyd‐Kirkup	2
3	A phase 1 first-in-human clinical trial of HMBD-002, an IgG4 monoclonal antibody targeting VISTA, in advanced solid tumors. 2023 ·Journal of Clinical Oncology ·Jordi Rodón,Joshua J. Gruber,Melinda L. Telli,Monica Mita,Alain C. Mita,Joseph W. Kim,Miguel A. Villalona‐Calero,Meera Patel,Shalini S. Yadav,Padmanee Sharma,Tom Haber,(unknown),(unknown),Bhushan Dharmadhikari,Dipti Thakkar,(unknown),Leah DiMascio,Eric K. Rowinsky,Piers J. Ingram,Jerome D. Boyd‐Kirkup	6
4	Rationally targeted anti-VISTA antibody that blockades the C-C’ loop region can reverse VISTA immune suppression and remodel the immune microenvironment to potently inhibit tumor growth in an Fc independent manner 2022 ·Journal for ImmunoTherapy of Cancer ·Dipti Thakkar,(unknown),Bhushan Dharmadhikari,Siyu Guan,(unknown),Shreya Kar,Nikhil Kumar Tulsian,Joshua J. Gruber,Leah DiMascio,Konrad Paszkiewicz,Piers J. Ingram,Jerome D. Boyd‐Kirkup	46
5	532 Anti-VISTA antibody HMBD-002 reprograms tumour associated macrophages and promotes cytotoxic T cell response 2022 ·Regular and Young Investigator Award Abstracts ·Bhushan Dharmadhikari,Dipti Thakkar,Olga Zharkova,(unknown),(unknown),Konrad Paszkiewicz,Piers J. Ingram,Jerome D. Boyd‐Kirkup	2
6	Abstract P197: An anti-HER3 antibody, HMBD-001, that uniquely binds to and blocks the HER3 heterodimerization interface, shows superior tumor growth inhibition in biomarker-defined preclinical cancer models including NRG1-fusion driven cancers 2021 ·Molecular Cancer Therapeutics ·Dipti Thakkar,(unknown),Shreya Kar,Namita Gandhi,Konrad Paszkiewicz,Piers J. Ingram,Jerome D. Boyd‐Kirkup	5
7	HMBD-002 is a novel, neutralizing, anti-VISTA antibody exhibiting strong preclinical efficacy and safety, being developed as a monotherapy and in combination with pembrolizumab. 2021 ·Journal of Clinical Oncology ·Leah DiMascio,Dipti Thakkar,Namita Gandhi,Siyu Guan,Eric K. Rowinsky,Piers J. Ingram,Jerome D. Boyd‐Kirkup	7
8	469 A phase 1 first in human study of HMBD-002, an IgG4 monoclonal antibody targeting VISTA, as a monotherapy and combined with pembrolizumab in patients with advanced solid malignancies 2021 ·Regular and Young Investigator Award Abstracts ·Leah DiMascio,Dipti Thakkar,Siyu Guan,Eric K. Rowinsky,Jordi Rodón,Joshua J. Gruber,Benjamin Musher,Joseph Kim,Alain C. Mita,Monica Mita,Piers J. Ingram,Jerome D. Boyd‐Kirkup	3
9	10D1F, an Anti-HER3 Antibody That Uniquely Blocks the Receptor Heterodimerization Interface, Potently Inhibits Tumor Growth Across a Broad Panel of Tumor Models 2020 ·Molecular Cancer Therapeutics ·Dipti Thakkar,Vicente Sancenón,(unknown),Siyu Guan,Zhihao Wu,(unknown),Konrad Paszkiewicz,Piers J. Ingram,Jerome D. Boyd‐Kirkup	13
10	Abstract 1729: Integrative immune profiling of syngeneic tumor models provides predictive immune signatures for treatment response with HMBD002, a novel anti-VISTA neutralizing antibody 2018 ·Cancer Research ·Jerome D. Boyd‐Kirkup,Dipti Thakkar,Konrad Paszkiewicz,Piers J. Ingram	6
11	HMBD004, a Novel Anti-CD47xCD33 Bispecific Antibody Displays Potent Anti-Tumor Effects in Pre-Clinical Models of AML 2017 ·Blood ·Jerome D. Boyd‐Kirkup,Dipti Thakkar,Peter Bräuer,Jianbiao Zhou,Wee Joo Chng,Piers J. Ingram	18
12	A Genome-wide Association Study of Dupuytren Disease Reveals 17 Additional Variants Implicated in Fibrosis 2017 ·The American Journal of Human Genetics ·Michael Ng,Dipti Thakkar,Lorraine Southam,Paul M. N. Werker,Roel A. Ophoff,Kerstin Becker,Michael Nothnagel,André Franke,Peter Nürnberg,(unknown),David Izadi,Hans Christian Hennies,Jagdeep Nanchahal,Eleftheria Zeggini,Dominic Furniss	61
13	Abstract 587: HMBD002, a novel neutralizing antibody targeting a specific epitope on the co-inhibitory immune checkpoint receptor VISTA, displays potent anti-tumor effects in pre-clinical models 2017 ·Cancer Research ·Piers J. Ingram,Dipti Thakkar,Jerome D. Boyd‐Kirkup	7
14	Gene expression profiles of changes underlying different-sized human rotator cuff tendon tears 2016 ·Journal of Shoulder and Elbow Surgery ·Salma Chaudhury,Zhidao Xia,Dipti Thakkar,Osnat Hakimi,Andrew Carr	42
15	Distribution and expression of type VI collagen and elastic fibers in human rotator cuff tendon tears 2014 ·Connective Tissue Research ·Dipti Thakkar,Tyler M. Grant,Osnat Hakimi,Andrew Carr	30
16	Ascorbic acid is essential for significant collagen deposition by human tenocytes in vitro 2014 ·ResearchSpace (University of Auckland) ·Osnat Hakimi,(unknown),Dipti Thakkar,Clarence Yapp,Andrew Carr	17
17	Proteomic Studies Coupled with RNAi Methodologies can Shed Further Light on the Downstream Effects of Telomerase in Glioma 2011 ·Cancer Investigation ·Dipti Thakkar,Leroy Shervington,Amal Shervington	6
18	Can hsp90α-Targeted siRNA Combined With TMZ Be a Future Therapy for Glioma? 2010 ·Cancer Investigation ·Nichola Cruickshanks,Leroy Shervington,Rahima Patel,Chinmay Munje,Dipti Thakkar,Amal Shervington	16
19	Proteomics: The Tool To Bridge the Gap between the Facts and Fables of Telomerase 2008 ·Critical Reviews™ in Oncogenesis ·Dipti Thakkar,Amal Shervington	1
20	The sensitization of glioma cells to cisplatin and tamoxifen by the use of catechin 2008 ·Molecular Biology Reports ·Amal Shervington,Vidya Pawar,(unknown),Dipti Thakkar,Rahima Patel	36

About Dipti Thakkar

Dipti Thakkar is a scholar working on Oncology, Immunology and Radiology, Nuclear Medicine and Imaging, having authored 21 papers that have together received 328 indexed citations. Recurring topics across this work include Monoclonal and Polyclonal Antibodies Research (9 papers), Cancer Immunotherapy and Biomarkers (8 papers) and Immune cells in cancer (4 papers). The work is most often cited by research in Orthopedics and Sports Medicine (55 citations), Developmental Biology (9 citations) and Immunology (74 citations). Dipti Thakkar has collaborated with scholars based in United Kingdom, United States and Singapore. Frequent co-authors include Andrew Carr, Osnat Hakimi, Piers J. Ingram, Jerome D. Boyd‐Kirkup, Amal Shervington, Rahima Patel, Tyler M. Grant, Salma Chaudhury, Zhidao Xia and Konrad Paszkiewicz. Their work appears in journals such as Journal of Clinical Oncology, Blood and The Journal of Immunology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact